GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

(Reuters) -The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus ...

GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for ...

GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV ...

Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to ...

GSK seeks EU approval for RSV vaccine for younger adults EU decision on expanded use expected by first half of 2026 June 13 (Reuters) - GSK (GSK.L), opens new tab has applied to the European ...

Drugmaker GSK said on Friday that its RSV vaccine, Arexvy, has been accepted for regulatory review by the European Medicines ...

Pfizer's RSV shot Abrysvo was cleared by the FDA last October for the 18 to 59 age group, extending its 2023 approval in the ...

GSK said on Friday the European Medicines Agency had accepted the drugmaker’s application to expand the use of ...